Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication

1. A method of screening human patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation after treatment with a selective serotonin reuptake inhibitor (SSRI) and detecting the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation (TESI) after treatment with a SSRI comprising:

(a) obtaining a sample of genetic material from the patients,

(b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation after treatment with a SSRI by performing an assay suitable for detection of a polymorphism, and

(c) identifying those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation after treatment with a SSRI based on the presence of the genotype associated with an increased risk of treatment-emergent suicidal ideation in (b),

wherein the genotype is characterized by a polymorphism in each of the following genes: glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A); neurotrophic tyrosine receptor kinase 2 (NTRK2); 5-hydroxytryptamine (serotonin) receptor 3B (HTR3B), glutamate receptor ionotropic AMPA 1 (GRIA1); papilin (PAPLN); and interleukin 28 receptor alpha (IL28RA);

wherein when the gene is GRIK2, the polymorphism is located within intron 1 of GRIK2, and the polymorphism is the cytosine allele of marker rs2518224;

wherein when the gene is GRIA3, the polymorphism is located within intron 3 of GRIA3, and the polymorphism is the guanine allele of marker rs4825476;

wherein when the gene is GR1N2A, the polymorphism is located within intron 3 of GRIN2A, and the polymorphism is the cytosine allele of marker rs3104703;

wherein when the gene is NTRK2, the polymorphism is located within intron 14 of NTRK2, and the polymorphism is the guanine allele of marker rs1573219;

wherein when the gene is HTR3B, the polymorphism is located within intron 6 of HTR3B, and the polymorphism is the guanine allele of marker rs2276307;

wherein when the gene is GRIA1, the polymorphism is located within intron 5 of GRIA1, and the polymorphism is the cytosine allele of marker rs4958672;

wherein when the gene is PAPLN, the polymorphism is located within intron 13 of PAPLN, and the polymorphism is the thymine allele of marker rs11628713;

wherein when the gene is IL28RA, the polymorphism is located within exon 7 of IL28RA, and the polymorphism is the guanine allele of marker rs10903034.

2. The method of claim 1 , wherein assaying comprises detecting the polymorphism by allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, or temperature gradient gel electrophoresis (TGGE), or combinations thereof.

3. The method of claim 1 , wherein assaying for the presence of the genotype comprises detecting the presence of at least one or more of the following polynucleotide sequences including SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, or combinations thereof.

4. The method of screening of claim 1 , wherein the human patients are identified after treatment with the SSRI, citalopram.